Results 71 to 80 of about 399,504 (355)

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]

open access: yes, 2017
BackgroundLiposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Doan, Ngan B   +9 more
core   +2 more sources

Komplex molekuláris genetikai vizsgálati algoritmus myeloproliferativ neoplasiák diagnosztikájában [PDF]

open access: yes, 2015
Introduction: Mutations in Janus kinase 2, calreticulin and thrombopoietin receptor genes have been identified in the genetic background of Philadelphia chromosome negative, "classic" myeloproliferative neoplasms.
Andrikovics, Hajnalka   +12 more
core   +1 more source

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

open access: yes, 2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J.   +3 more
openaire   +2 more sources

Mechanisms of parasite‐mediated disruption of brain vessels

open access: yesFEBS Letters, EarlyView.
Parasites can affect the blood vessels of the brain, often causing serious neurological problems. This review explains how different parasites interact with and disrupt these vessels, what this means for brain health, and why these processes matter. Understanding these mechanisms may help us develop better ways to prevent or treat brain infections in ...
Leonor Loira   +3 more
wiley   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

open access: yesHepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou   +15 more
wiley   +1 more source

JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician

open access: yesJournal of Family Medicine and Primary Care
Guidelines for primary care clinicians on monitoring and safety guidelines regarding Janus kinase and tyrosine kinase 2 inhibitors in the treatment of inflammatory skin conditions are often unclear.
Abigail Beard, Shannon C. Trotter
doaj   +1 more source

Differential Tissue Response to Growth Hormone in Mice [PDF]

open access: yes, 2018
Growth hormone (GH) has been shown to act directly on multiple tissues throughout the body. Historically, it was believed that GH acted directly in the liver and only indirectly in other tissues via insulin‐like growth hormone 1 (IGF‐1).
Banerjee, Ronadip R.   +4 more
core   +2 more sources

Janus Kinase 2: An Epigenetic 'Writer' that Activates Leukemogenic Genes [PDF]

open access: yesJournal of Molecular Cell Biology, 2010
Activation of Janus kinase 2 (JAK2) plays a critical role in normal hematopoiesis and leukemogenesis. Dawson et al. (2009; JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822) report that JAK2 performs this function by displacing the heterochromatin protein HP1α from chromatin through phosphorylation of histone ...
Jin, He, Yi, Zhang
openaire   +2 more sources

TREX1, a predator for treating MSI‐H tumors?

open access: yesMolecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya   +2 more
wiley   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

open access: yesHepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy